---
title: "Intellia Therapeutics (NTLA) Gets a Hold from Wedbush"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/292339149.md"
description: "Wedbush maintained a Hold rating on Intellia Therapeutics (NTLA) with a $17.00 price target. Meanwhile, TipRanks launched a new ETF (NYSE: RANK) tracking its US Momentum Analysts Index of 50 large U.S. companies. Despite Wedbush's stance, the broader analyst consensus for Intellia remains a Moderate Buy, with an average price target of $21.38."
datetime: "2026-07-10T14:05:28.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/292339149.md)
  - [en](https://longbridge.com/en/news/292339149.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/292339149.md)
generator: "portal-rs"
---

# Intellia Therapeutics (NTLA) Gets a Hold from Wedbush

In a report released today, from Wedbush maintained a Hold rating on Intellia Therapeutics, with a price target of $17.00.

### TipRanks Welcomes a New ETF – NYSE:RANK

-   TipRanks has entered a new arena in the investing world, powering the index of an ETF based on its unique data now trading under the ticker RANK on the NYSE.
-   RANK tracks the performance of the TipRanks US Momentum Analysts Index, a rules-based index of 50 large U.S. companies.

Intellia Therapeutics has an analyst consensus of Moderate Buy, with a price target consensus of $21.38.

### Related Stocks

- [NTLA.US](https://longbridge.com/en/quote/NTLA.US.md)
- [RANK.US](https://longbridge.com/en/quote/RANK.US.md)

## Related News & Research

- [Intellia awards 163,100 RSUs to 41 new employees under inducement plan](https://longbridge.com/en/news/298071320.md)
- [Intellia Therapeutics to present at Morgan Stanley Global Healthcare Conference](https://longbridge.com/en/news/298034989.md)
- [There’s Finally 1 Covered Call ETF I Like. Here’s What Makes It Stand Out.](https://longbridge.com/en/news/297683764.md)
- [Intellia Therapeutics (NTLA) Stock May Be Fully Priced Despite Its 92% Slide](https://longbridge.com/en/news/297101357.md)
- [Intellia Therapeutics Secures Non-Dilutive Debt Facility with OrbiMed for up to $400 Million | NTLA Stock News](https://longbridge.com/en/news/298041551.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**